Skip Navigation

PROTAC® Platform

The pioneer in targeted protein degradation

Arvinas is the pioneer of targeted protein degradation technology - our founder invented the technology. We have turned targeted protein degradation into one of the most promising areas of medical research and are establishing a new scientific frontier by challenging the perceived limits of drug discovery. We are engineering an expansive pipeline of proteolysis targeting chimeras, or PROTAC protein degraders, designed to harness the body’s own natural protein disposal system (the ubiquitin proteasome system) to selectively and efficiently degrade and remove disease-causing proteins.

We create proteolysis targeting chimeras (PROTAC degraders) Watch Video

Leveraging nature’s protein disposal system

As part of this natural protein disposal system, a group of proteins, called E3 ligases, naturally recognize mutated and misfolded proteins, or proteins that are no longer needed, and tag them with ubiquitin protein molecules. This process of tagging specific proteins directs the target proteins to the proteasome, a large complex that degrades the protein into small peptides. PROTAC protein degraders work by recruiting an E3 ligase to tag the target protein so that it can be identified for ubiquitination and degradation by the proteasome. After the protein is degraded, the drug is released to continue its degradation mission.

  • Targeting the “Undruggable” - We’ve demonstrated a consistent and reproducible ability to degrade proteins, successfully degrading ~ 95% of those we’ve targeted. PROTAC protein degraders can potentially target proteins that have been “undruggable” by traditional small molecule therapies.
  • Multiple routes of administration - We can generate PROTAC protein degraders to be delivered orally, via injection, or via infusion, depending on the disease and need.
  • Crossing the blood/brain barrier - In preclinical studies, our PROTAC protein degraders have successfully penetrated the blood-brain barrier, a key step in developing drugs to treat neurodegenerative targets.
  • Benefits of small molecules - In contrast to some other novel modalities, PROTAC protein degraders have broad distribution in the body and can be manufactured using well-understood processes.